Tevogen Bio Holdings 주식 (NASDAQ: TVGN)

에 대한 최신 뉴스 Tevogen Bio Holdings (NASDAQ:TVGN) 주식

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Exclusives

Trading Ideas

AAPL

AMZN

DRUG

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 10월에 벤징가 프로에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 실적은 11월 1일 기준이며 배당금은 포함되지 않았다.

독점: 벤징가 프로에서 10월 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, DJT 순위는?

Tevogen Bio Holdings Inc

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>)</h3>
<ul>
<li>Dividend Yield: 10.33%</li>
<li>RBC Capital analyst Michael Carroll maintained an Underperform rating and cut the price target from $12 to $11 on March 10, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and lowered the price target from $14 to $13 on Dec. 6, 2024. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Feb. 25, Easterly Government Props posted fourth-quarter FFO of 29 cents, in-line with estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest DEA <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119.png" alt="" class="wp-image-824364" style="width:475px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119-768x710.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">Park Hotels &amp; Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>)</h3>
<ul>
<li>Dividend Yield: 9.17%</li>
<li>UBS analyst Robin Farley maintained a Neutral rating and cut the price target from $15 to $13 on Feb. 3, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Wolfe Research analyst Keegan Carl downgraded the stock from Outperform to Peer Perform on Sept. 26, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Feb. 19, Park Hotels &amp; Resorts posted better-than-expected quarterly revenue.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">latest PK news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="900" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120.png" alt="" class="wp-image-824366" style="width:492px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120-768x714.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
<h3 class="wp-block-heading">Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 7.60%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Neutral to Underperform and cut the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Wells Fargo analyst James Feldman assumed an Underweight rating and raised the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">HR news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121.png" alt="" class="wp-image-824369" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121-768x712.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/03/44300558/jim-cramer-arthur-j-gallagher-is-solid-this-industrial-company-is-fantastic">Jim Cramer: Arthur J. Gallagher Is &#8216;Solid,&#8217; This Industrial Company Is &#8216;Fantastic&#8217;</a></li>
</ul>

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields

Needham analyst Quinn Bolton reiterates D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) with a Buy and maintains $8.5 price target.

Reiteration

QBTS

Needham Reiterates Buy on D-Wave Quantum, Maintains $8.5 Price Target

Needham analyst Quinn Bolton reiterates Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Buy and maintains $54 price target.

SMTC

Needham Reiterates Buy on Semtech, Maintains $54 Price Target

Piper Sandler analyst Peter Keith maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Neutral and raises the price target from $79 to $81.

Piper Sandler Maintains Neutral on Dollar Gen, Raises Price Target to $81

Piper Sandler analyst Quinton Gabrielli maintains Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Overweight and lowers the price target from $268 to $200.

MANH

Piper Sandler Maintains Overweight on Manhattan Associates, Lowers Price Target to $200

Needham analyst Chris Pierce reiterates Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) from Hold to Hold.

BLNK

Needham Reiterates Hold on Blink Chargingto Hold

Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) with a Buy and maintains $8 price target.

GBIO

Needham Reiterates Buy on Generation Bio, Maintains $8 Price Target

AAOI: 92% &#x7C; <a href="https://www.benzinga.com//node/44317133">Applied Optoelectronics shares are trading higher after the company announced a warrant issuance agreement transaction with Amazon for 7,945,399 shares.</a>
&nbsp;
SMTC: 13% &#x7C; <a href="https://www.benzinga.com//node/44316016">Semtech shares are trading higher after the company reported better-than-expected Q4 financial results.</a>
&nbsp;
RBRK: 21% &#x7C; <a href="https://www.benzinga.com//node/44315877">Rubrik shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 guidance above estimates.</a>

Movers

AAOI

RBRK

Market-Moving News for March 14th

Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) reported stronger-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/ulta/earnings">financial results on Thursday</a>.
Ulta Beauty reported fourth-quarter revenue of $3.49 billion, beating the consensus estimate of $3.46 billion. The specialty beauty retailer reported fourth-quarter earnings of $8.46 per share, beating analyst estimates of $7.14 per share, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
"I am incredibly optimistic about the future of Ulta Beauty, as I believe we have the right elements to drive our success — a strong business model, an ambitious long-term plan, and passionate associates who bring our brand to life for our guests every day," said Kecia Steelman, president and CEO of Ulta Beauty.
Ulta Beauty expects fiscal year 2025 revenue of $11.5 billion to $11.6 billion versus estimates of $11.67 billion, according to Benzinga Pro. The company anticipates full-year earnings of $22.50 to $22.90 per share versus estimates of $23.50 per share.
Ulta Beauty shares fell 4.5% to close at $314.47 on Thursday.
These analysts made changes to their price targets on Ulta Beauty following earnings announcement.
<ul>
<li>Morgan Stanley analyst Simeon Gutman maintained Ulta Beauty with an Overweight rating and lowered the price target from $500 to $460.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained the stock with an Outperform rating and cut the price target from $500 to $460.</li>
</ul>
Considering buying ULTA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-1024x611.png" alt="" class="wp-image-824610" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44323490/ulta-beauty-docusign-and-3-stocks-to-watch-heading-into-friday">Ulta Beauty, DocuSign And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Earnings

ULTA

Ulta Beauty Analysts Slash Their Forecasts After Q4 Results

Telsey Advisory Group analyst Dana Telsey maintains Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) with a Market Perform and maintains $5 price target.

CURV

Telsey Advisory Group Maintains Market Perform on Torrid Holdings, Maintains $5 Price Target

Palantir Technologies Partners With R1 To Launch R37 AI Lab, Revolutionizing Healthcare Financial Performance With Advanced Automation Solutions

Gogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. The company reported quarterly sales of $137.799 million which beat the analyst consensus estimate of $97.352 million by 41.55 percent. This is a 40.88 percent increase over sales of $97.810 million the same period last year.

Earnings Beats

GOGO

CORRECTION: Gogo Q4 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $137.799M Beat $97.352M Estimate

Needham analyst Chris Pierce maintains Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) with a Buy and lowers the price target from $1.5 to $1.

Needham Maintains Buy on Urgently, Lowers Price Target to $1

Bristol Myers Squibb Says European Commission Granted Approval To Breyanzi For Treatment Of Adult Patients With Relapsed Or Refractory Follicular Lymphoma

Wayfair Announces Plans For Second Large-Format Store In Atlanta, Set To Open In 2026, Offering 150,000 Square Feet Of Home Furniture And Decor

Telsey Advisory Group analyst Joseph Feldman maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Outperform and maintains $250 price target.

Telsey Advisory Group Maintains Outperform on Dick's Sporting Goods, Maintains $250 Price Target

IRIX

Iridex Says Not Aware Of Any Material Developments Or Changes To Operating Or Financial Condition For Recent Stock Price Volatility

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Expects To Receive A Prepayment From Its U.S. Distributor For  INSPIRA ART100 Systems For Planned Deployment In Select Hospitals

2025 Financial Guidance
Total revenue in the range of $870 million to $910 million.
Adjusted EBITDA &nbsp;in the range of $200 million to $220 million, reflecting operating expenses of approximately $25 million for strategic and operational initiatives, including Gogo 5G and Gogo Galileo.
Free Cash Flow in the range of $60 million to $90 million, including $70 million of strategic initiatives, net of reimbursements tied to the FCC Reimbursement Program.
Capital expenditures of approximately $60 million, including $45 million for strategic initiatives including Gogo 5G, Gogo Galileo and the LTE network build, and excluding $20 million in capex reimbursement from the FCC program.

Guidance

Gogo Expects FY25 Revenue Of $870M-$910M Vs $447.8M Est

General

Buckle's Q4 Comparable Store Sales Increases 3.9%

Press Releases

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Health Care

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Management

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

Financing

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

Legal

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

TVGNW

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Amarin Corp

Anika Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

Cargo Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharma

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Genfit

Inhibrx Biosciences

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Kodiak Sciences

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lyell Immunopharma

Monopar Therapeutics

Nuvectis Pharma

Puma Biotechnology

Prime Medicine

AVITA Medical

Rezolute

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tango Therapeutics

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Y-mAbs Therapeutics

D. Boral Capital

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1" target="_blank" rel="noopener" data-google-interstitial="false">개별 종목</a>에 대한 최신 뉴스를 확인할 수 있는 소스이다.
2024년 10월에 벤징가 프로에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 실적은 11월 1일 기준이며 배당금은 포함되지 않았다.
1. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
&#8211; 현재 가격: $248.98 
&#8211; 52주 가격 범위: $138.80 ~ $273.54 
&#8211; 연초 대비 수익률: +0.2% 
&#8211; <a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow" target="_blank" rel="noopener" data-google-interstitial="false">7월</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noopener" data-google-interstitial="false">8월</a>/<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple" target="_blank" rel="noopener" data-google-interstitial="false">9월</a> 순위: 1위/3위/3위
2. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
&#8211; 현재 가격: $135.37 
&#8211; 52주 가격 범위: $44.90 ~ $144.42 
&#8211; 연초 대비 수익률: +181.0% 
&#8211; 7월/8월/9월 순위: 2위/1위/1위
3. 트럼프 미디어 앤 테크놀로지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
&#8211; 현재 가격: $30.56 
&#8211; 52주 가격 범위: $11.75 ~ $79.38 
&#8211; 연초 대비 수익률: +75.7% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/20위
4. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
&#8211; 현재 가격: $571.04 
&#8211; 52주 가격 범위: $426.56 ~ $586.12 
&#8211; 연초 대비 수익률: +20.8% 
&#8211; 7월/8월/9월 순위: 3위/2위/2위
5. 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
&#8211; 현재 가격: $26.05 
&#8211; 52주 가격 범위: $24.92 ~ $122.90 
&#8211; 연초 대비 수익률: -8.8% 
&#8211; 7월/8월/9월 순위: 19위/4위/7위
6. 브라이트 마인즈 바이오사이언시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>)
&#8211; 현재 가격: $48.18 
&#8211; 52주 가격 범위: $0.93 ~ $79.02 
&#8211; 연초 대비 수익률: +2,518.5% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/상위 20위 미포함
7. 어드밴스드 마이크로 디바이시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
&#8211; 현재 가격: $141.86 
&#8211; 52주 가격 범위: $110.22 ~ $227.30 
&#8211; 연초 대비 수익률: +2.4% 
&#8211; 7월/8월/9월 순위: 14위/8위/상위 20위 미포함
8. 애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
&#8211; 현재 가격: $222.91 
&#8211; 52주 가격 범위: $164.08 ~ $237.49 
&#8211; 연초 대비 수익률: +20.1% 
&#8211; 7월/8월/9월 순위: 7위/6위/4위
9. 테보젠 바이오 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>)
&#8211; 현재 가격: $2.37 
&#8211; 52주 가격 범위: $0.26 ~ $21.09 
&#8211; 연초 대비 수익률: -78.7% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/상위 20위 미포함
10. 오클로 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)
&#8211; 현재 가격: $21.67 
&#8211; 52주 가격 범위: $5.35 ~ $28.12 
&#8211; 연초 대비 수익률: +104.4% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/상위 20위 미포함
주목할 만한 주식들:다음 주식들은 2024년 10월 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>에서 11위에서 20위까지 가장 많이 검색된 종목들이다.
11. 아마존닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
12. 마이크로소프트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)
13. 메타 플랫폼 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
14. 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
15. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
16. 마이크로스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)
17. 젠프렉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>)
18. 소파이 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)
19. 보잉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)
20. 테라울프 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>)
중요한 이유 (Why It&#8217;s Important): 테슬라는 사이트에서 가장 많이 검색되는 티커 중 하나로, 10월에 벤징가 프로에서 가장 많이 검색된 종목이 되었다. 주가는 지난 두 달 동안 3위를 기록했으나, 7월에는 1위를 차지한 바 있다.
엔비디아는 10월에 2위로 순위가 하락했으며, 지난 두 달 동안 1위를 기록했다. 이 기술 대기업은 잠시 동안 애플과 마이크로소프트를 제치고 <a href="https://www.benzinga.com/markets/equities/24/10/41551461/nvidia-overtakes-apple-as-worlds-most-valuable-company-again" target="_blank" rel="noopener" data-google-interstitial="false">세계에서 가장 가치 있는 회사</a>로 등극하기도 했다.
10월의 가장 큰 변동 종목 중 하나는 트럼프 미디어 앤 테크놀로지 그룹으로, 전 대통령 도널드 트럼프가 공동 설립한 미디어 회사이다. 주식은 선거일을 앞두고 최근 몇 주 동안 급등했다. 트럼프의 2024년 대통령 선거 승리 확률은 <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41635149/2024-election-odds-on-polymarket-kalshi-show-trump-will-win-why-they-might-be-wrong" target="_blank" rel="noopener" data-google-interstitial="false">예측 시장</a>과 스포츠 베팅 앱에서 상승했다.
이 주식은 또한 높은 공매도 비율을 가진 <a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-" target="_blank" rel="noopener" data-google-interstitial="false">공매도 압박 종목(</a><a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-" target="_blank" rel="noopener" data-google-interstitial="false">short-squeeze</a><a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-" target="_blank" rel="noopener" data-google-interstitial="false">)</a>으로 주목받았다. 트럼프가 2024년 선거에서 승리할 경우 주가는 급등할 수 있다. 반대로, 트럼프가 선거에서 패할 경우 주가는 크게 하락할 수 있다.
트럼프 미디어 앤 테크놀로지 그룹은 11월에도 벤징가 프로에서 가장 많이 검색된 티커 중 하나가 될 가능성이 높으며, 선거일은 11월 5일이다. 이 주식은 9월에 20위에 올랐고, 8월이나 7월에는 상위 20위에 포함되지 않았다.
SPDR S&amp;P 500 ETF Trust는 지난 두 달간 2위에서 4위로 하락했으며, 이는 위에 언급된 주식들에 대한 관심 증가 때문일 가능성이 크고, S&amp;P 500 시장 지수에 대한 관심 감소 때문은 아니다. 또한, 나스닥 100 지수를 추적하는 Invesco QQQ Trust ETF는 6위에서 15위로 하락하여, ETF와 시장 지수에 대한 관심이 줄어들었을 가능성을 나타낸다.
상위 10위에 새롭게 진입한 주식은 브라이트 마인즈 바이오사이언시스, 테보젠 바이오 및 오클로로, 이들은 이전에 어떤 달에도 상위 20위에 포함된 적이 없다. 테보젠의 주식은 2024년에 크게 하락했으며, 브라이트 마인즈와 오클로는 각각 2024년에 100% 이상 상승했다.
AMD도 7위로 상위 10위에 재진입했으며, 이는 9월에 상위 20위에서 탈락한 후의 일이다. 이 주식은 2024년 동안 매달 상위 10위와 상위 20위 사이에서 계속 오르락내리락하고 있다.
상위 10위에서 Invesco QQQ와 함께 탈락한 주식은 휠러 리얼 에스테이트 인베스트먼트 트러스트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>), 갈메드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>), 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) 및 인튜이티브 머신스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)이다.
전반적으로 10월 한 달 동안 9월의 상위 10위 주식 중 5개가 동일하게 유지되었고, 9월의 상위 20위 주식 중 8개가 동일하게 유지되었다.
다음 기사:
<ul class="block core-block">
<li><a href="https://www.benzinga.com/general/education/24/10/41665149/these-10-stocks-were-s-p-500s-top-performers-in-bidens-first-year-could-the-trend-continue-if-h" target="_blank" rel="noopener" data-google-interstitial="false">These 10 Stocks Were S&amp;P 500's Top Performers In Biden's First Year: Could Trend Continue If Harris Wins 2024 Election?</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Tevogen Bio Holdings

뉴스

에 대한 최신 뉴스 Tevogen Bio Holdings (NASDAQ:TVGN) 주식

월요일, 11월 04, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌